Alaide Chieffo1, Anna Sonia Petronio2, Julinda Mehilli3, Jaya Chandrasekhar4, Samantha Sartori4, Thierry Lefèvre5, Patrizia Presbitero6, Piera Capranzano7, Didier Tchetche8, Alessandro Iadanza9, Gennaro Sardella10, Nicolas M Van Mieghem11, Emanuele Meliga12, Nicholas Dumonteil13, Chiara Fraccaro14, Daniela Trabattoni15, Ghada Mikhail16, Samin Sharma17, Maria Cruz Ferrer18, Christoph Naber19, Peter Kievit20, Usman Baber4, Clayton Snyder4, Madhav Sharma4, Marie Claude Morice5, Roxana Mehran21. 1. Department of Cardiology, San Raffaele Scientific Institute, Milan, Italy. 2. Department of Cardiology, AOUP Cisanello, University Hospital, Pisa, Italy. 3. Department of Cardiology, Ludwig-Maximilians-University of Munich, Munich, Germany. 4. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Department of Cardiology, Institut Hospitalier Jacques Cartier, Ramsay Générale de Santé, Massy, France. 6. Department of Cardiology, Istituto Clinico Humanitas, Milan, Italy. 7. Department of Cardiology, University of Catania, Catania, Italy. 8. Department of Cardiology, Clinique Pasteur, Toulouse, France. 9. Department of Cardiology, Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Siena, Italy. 10. Department of Cardiology, Policlinico "Umberto I," Sapienza University of Rome, Rome, Italy. 11. Department of Cardiology, Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands. 12. Department of Cardiology, Mauriziano Hospital, Turin, Italy. 13. Department of Cardiology, Rangueil University Hospital, Toulouse, France. 14. Department of Cardiology, University of Padova, Padova, Italy. 15. Department of Cardiology, Centro Cardiologico Monzino, Milan, Italy. 16. Department of Cardiology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom. 17. Department of Cardiology, Mount Sinai Hospital, New York, New York. 18. Department of Cardiology, Hospital Universitario Miguel Servet, Zaragoza, Spain. 19. Department of Cardiology, Contilia Heart and Vascular Centre, Elisabeth Krankenhaus, Essen, Germany. 20. Department of Cardiology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. 21. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: roxana.mehran@mountsinai.org.
Abstract
OBJECTIVES: This study sought to examine the safety and performance of contemporary transcatheter aortic valve replacement (TAVR) in an exclusive all-women TAVR population, and to further investigate the potential impact of female sex-specific characteristics on composite 1-year clinical outcomes. BACKGROUND: Women comprise ≥50% patients undergoing TAVR. Several data have shown the noninferiority of TAVR compared with surgical aortic valve replacement for symptomatic significant aortic stenosis, but no study so far has been specifically powered to detect differences by sex. METHODS: The WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) registry is a multinational, prospective, observational registry of women undergoing TAVR for significant aortic stenosis, across 18 sites in Europe and 1 site in the United States, between January 2013 and December 2015. The primary Valve Academic Research Consortium (VARC)-2 efficacy endpoint was a composite of mortality, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure or valve-related dysfunction beyond 30 days. Secondary endpoints included composite 1-year death or stroke. Predictors of 1-year outcomes were determined using Cox regression methods. RESULTS: A total of 1,019 intermediate to high-risk women, with mean age 82.5 ± 6.3 years, mean European System for Cardiac Operative Risk Evaluation (EuroSCORE) I 17.8 ± 11.7% and mean Society of Thoracic Surgeons score 8.3 ± 7.4% were enrolled. TAVR was performed via transfemoral access in 90.6% and new-generation devices were used in 42.1%. The primary VARC-2 efficacy composite endpoint occurred in 111 (10.9%) patients beyond 30 days and in 167 (16.5%) patients at 1 year. The incidence of 1-year death or stroke was 13.9% (n = 141). Death occurred in 127 (12.5%) patients and stroke in 22 (2.2%) patients. Prior coronary revascularization (hazard ratio [HR]: 1.72; 95% confidence interval [CI]: 1.17 to 2.52; p = 0.006) and EuroSCORE I (HR: 1.02; 95% CI: 1.00 to 1.04; p = 0.027) were independent predictors of the VARC-2 efficacy endpoint. Similarly, EuroSCORE I (HR: 1.02; 95% CI: 1.00 to 1.04; p = 0.013), baseline atrial fibrillation (HR: 1.58; 95% CI: 1.07 to 2.33; p = 0.022), and prior percutaneous coronary intervention (HR: 1.50; 95% CI: 1.03 to 2.19; p = 0.035) were independent predictors of 1-year death or stroke. After adjustment, no significant association was observed between history of pregnancy or any sex-specific factors and 1-year TAVR outcomes. CONCLUSIONS: Intermediate to high-risk women enrolled in this first ever all-women contemporary TAVR registry experienced a 1-year VARC-2 composite efficacy endpoint of 16.5%, with a low incidence of 1-year mortality and stroke. Prior revascularization and EuroSCORE I were independent predictors of the VARC-2 efficacy endpoint, whereas EuroSCORE I, baseline atrial fibrillation, and prior percutaneous coronary intervention were independent predictors of the 1-year death or stroke.
OBJECTIVES: This study sought to examine the safety and performance of contemporary transcatheter aortic valve replacement (TAVR) in an exclusive all-women TAVR population, and to further investigate the potential impact of female sex-specific characteristics on composite 1-year clinical outcomes. BACKGROUND:Women comprise ≥50% patients undergoing TAVR. Several data have shown the noninferiority of TAVR compared with surgical aortic valve replacement for symptomatic significant aortic stenosis, but no study so far has been specifically powered to detect differences by sex. METHODS: The WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) registry is a multinational, prospective, observational registry of women undergoing TAVR for significant aortic stenosis, across 18 sites in Europe and 1 site in the United States, between January 2013 and December 2015. The primary Valve Academic Research Consortium (VARC)-2 efficacy endpoint was a composite of mortality, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure or valve-related dysfunction beyond 30 days. Secondary endpoints included composite 1-year death or stroke. Predictors of 1-year outcomes were determined using Cox regression methods. RESULTS: A total of 1,019 intermediate to high-risk women, with mean age 82.5 ± 6.3 years, mean European System for Cardiac Operative Risk Evaluation (EuroSCORE) I 17.8 ± 11.7% and mean Society of Thoracic Surgeons score 8.3 ± 7.4% were enrolled. TAVR was performed via transfemoral access in 90.6% and new-generation devices were used in 42.1%. The primary VARC-2 efficacy composite endpoint occurred in 111 (10.9%) patients beyond 30 days and in 167 (16.5%) patients at 1 year. The incidence of 1-year death or stroke was 13.9% (n = 141). Death occurred in 127 (12.5%) patients and stroke in 22 (2.2%) patients. Prior coronary revascularization (hazard ratio [HR]: 1.72; 95% confidence interval [CI]: 1.17 to 2.52; p = 0.006) and EuroSCORE I (HR: 1.02; 95% CI: 1.00 to 1.04; p = 0.027) were independent predictors of the VARC-2 efficacy endpoint. Similarly, EuroSCORE I (HR: 1.02; 95% CI: 1.00 to 1.04; p = 0.013), baseline atrial fibrillation (HR: 1.58; 95% CI: 1.07 to 2.33; p = 0.022), and prior percutaneous coronary intervention (HR: 1.50; 95% CI: 1.03 to 2.19; p = 0.035) were independent predictors of 1-year death or stroke. After adjustment, no significant association was observed between history of pregnancy or any sex-specific factors and 1-year TAVR outcomes. CONCLUSIONS: Intermediate to high-risk women enrolled in this first ever all-women contemporary TAVR registry experienced a 1-year VARC-2 composite efficacy endpoint of 16.5%, with a low incidence of 1-year mortality and stroke. Prior revascularization and EuroSCORE I were independent predictors of the VARC-2 efficacy endpoint, whereas EuroSCORE I, baseline atrial fibrillation, and prior percutaneous coronary intervention were independent predictors of the 1-year death or stroke.
Authors: Jacqueline T DesJardin; Joanna Chikwe; Rebecca T Hahn; Judy W Hung; Francesca N Delling Journal: Circ Res Date: 2022-02-17 Impact factor: 17.367
Authors: Martijn S van Mourik; Nathalie van der Velde; Giulio Mannarino; Marie-Pierre Thibodeau; Jean-Bernard Masson; Gennaro Santoro; Jan Baan; Sofie Jansen; Jana Kurucova; Martin Thoenes; Cornelia Deutsch; Andreas W Schoenenberger; Andrea Ungar; Peter Bramlage; M Marije Vis Journal: J Geriatr Cardiol Date: 2019-06 Impact factor: 3.327
Authors: Christopher Hohmann; Marion Ludwig; Jochen Walker; Hendrik Wienemann; Stephan Baldus; Roman Pfister Journal: Front Cardiovasc Med Date: 2021-12-23
Authors: Antonio Mangieri; Claudio Montalto; Matteo Pagnesi; Giuseppe Lanzillo; Ozan Demir; Luca Testa; Antonio Colombo; Azeem Latib Journal: Front Cardiovasc Med Date: 2018-07-03